Patrizio Castagnola
Overview
Explore the profile of Patrizio Castagnola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bellitto D, Bozzo M, Ravera S, Bertola N, Rosamilia F, Milia J, et al.
Redox Biol
. 2025 Mar;
81:103544.
PMID: 40023981
Alexander disease (AxD) is a rare leukodystrophy caused by heterozygous mutations in the GFAP gene. To date, several in vitro and in vivo models have been generated in an attempt...
2.
Arnaldi P, Casarotto E, Relucenti M, Bellese G, Gagliani M, Crippa V, et al.
Microsc Res Tech
. 2024 Jul;
87(11):2785-2800.
PMID: 38988205
Three-dimensional (3D) spheroid models aim to bridge the gap between traditional two-dimensional (2D) cultures and the complex in vivo tissue environment. These models, created by self-clustering cells to mimic a...
3.
Di Lisa D, Cortese K, Chiappalone M, Arnaldi P, Martinoia S, Castagnola P, et al.
Front Bioeng Biotechnol
. 2024 Apr;
12:1368851.
PMID: 38638322
Breast cancer is a significant global health concern, with the overexpression of human epidermal growth factor receptor 2 (HER2/ERBB2) being a driver oncogene in 20%-30% of cases. Indeed, HER2/ERBB2 plays...
4.
Pentenero M, Castagnola P, Castillo F, Isaevska E, Sutera S, Gandolfo S
Head Neck
. 2023 Aug;
45(10):2589-2604.
PMID: 37563936
Background: This prospective observational study investigated the determinants of malignant transformation (MT) in localized oral leukoplakia (OL) and proliferative verrucous leukoplakia (PVL). Methods: Demographic, clinical, histological, and DNA ploidy status...
5.
Cortese K, Ponassi M, Profumo A, Vargas G, Iervasi E, Gagliani M, et al.
Membranes (Basel)
. 2023 Jun;
13(6).
PMID: 37367744
Trastuzumab (Tz), an antibody targeting ERBB2, has significantly improved the prognosis for breast cancer (BCa) patients with overexpression of the ERBB2 receptor. However, Tz resistance poses a challenge to patient...
6.
Bellese G, Tagliatti E, Gagliani M, Santamaria S, Arnaldi P, Falletta P, et al.
Biochem Pharmacol
. 2023 Jun;
213:115633.
PMID: 37269887
Neratinib (NE) is an irreversible pan-ERBB tyrosine kinase inhibitor used to treat breast cancers (BCa) with amplification of the ERBB2/HER2/Neu gene or overexpression of the ERBB2 receptor. However, the mechanisms...
7.
Amaro A, Gangemi R, Emionite L, Castagnola P, Filaci G, Jager M, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765842
Background: Metastatic uveal melanoma (MUM) is a highly aggressive, therapy-resistant disease. Driver mutations in Gα-proteins GNAQ and GNA11 activate MAP-kinase and YAP/TAZ pathways of oncogenic signalling. MAP-kinase and MEK-inhibitors do...
8.
Bari E, Ferrera F, Altosole T, Perteghella S, Mauri P, Rossi R, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36697251
Background: The current challenge for immunotherapies is to generate effective antitumor immunity. Since tumor immune escape mechanisms do not impact pre-existing and consolidated immune responses, we tested the hypothesis of...
9.
Viale M, Lentini G, Gangemi R, Castagnola P, Milani G, Ravera S, et al.
Molecules
. 2022 Nov;
27(22).
PMID: 36431971
In a previous paper, we demonstrated the synergistic action of the anti-ischemic lubeluzole (Lube S) on the cytotoxic activity of doxorubicin (Dox) and paclitaxel in human ovarian cancer A2780 and...
10.
Wang W, Di Nisio E, Licursi V, Cacci E, Lupo G, Kokaia Z, et al.
Life (Basel)
. 2022 Nov;
12(11).
PMID: 36362982
We analyzed the morphology and the transcriptomic changes of human neural stem progenitor cells (hNSPCs) grown on laminin in adherent culture conditions and subjected to simulated microgravity for different times...